WASHINGTON, D.C. – President Donald Trump believes that reductions in prescription drug prices will have a significant impact on the midterm elections.

Trump, along with top healthcare officials and Pfizer CEO Albert Bourla, announced in an Oval Office press conference that the pharmaceutical company agreed to allow state Medicaid programs access to drugs at most-favored-nation prices.

For instance, Eucrisa, a medication used to treat dermatitis, will see an 80 percent price reduction under the MFN cost, according to a White House fact sheet. Rheumatoid arthritis medication Xeljanz and migraine medication Zavzpret will see a 40 percent and 50 percent price drop, respectively.

Trump noted that another company would be visiting the White House next week for a similar announcement.

“We’

See Full Page